^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-5322

    i
    Other names: JNJ-5322, JNJ-79635322, JNJ5322, JNJ79635322, JNJ 5322, JNJ 79635322
    Company:
    J&J
    Drug class:
    CD3 agonist, BCMA inhibitor, GPRC5D inhibitor
    Related drugs:
    2d
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    JNJ-5322 • Tecvayli (teclistamab-cqyv)
    2ms
    Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. (PubMed, Blood)
    The potent and selective antitumor activity of ramantamig, with a clonal depleting ability in vitro, ex vivo, and in vivo warrants clinical evaluation of its ability to induce durable responses in myeloma. Phase 1 clinical trials are ongoing for patients with relapsed/refractory MM (NCT05652335, NCT06768489).
    Journal
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    JNJ-5322
    6ms
    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Recruiting, Janssen Research & Development, LLC | N=100 --> 140
    Enrollment change
    |
    lenalidomide • Darzalex (daratumumab) • pomalidomide • JNJ-5322
    7ms
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial primary completion date
    |
    JNJ-5322
    11ms
    A Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC
    New P1 trial
    |
    Darzalex (daratumumab) • pomalidomide • JNJ-5322
    1year
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trispecific
    |
    JNJ-5322
    almost2years
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=170, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2025 --> Apr 2026
    Trial completion date • Trispecific
    |
    JNJ-5322
    2years
    Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma (ASH 2023)
    JNJ-79635322 is a potential first-in-class trispecific antibody targeting BCMA and GPRC5D with the ability to deplete dual and single target expressing MM clones in preclinical studies vitro and in vivo. A Phase 1 dose-escalating study of JNJ-79635322 in myeloma patients is ongoing (NCT05652335).
    Trispecific
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    GPRC5D expression
    |
    JNJ-5322
    2years
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=169, Recruiting, Janssen Research & Development, LLC | N=90 --> 169
    Enrollment change • Trispecific
    |
    JNJ-5322